Syntara Limited · ASX:SNT
Syntara — Investor Presentation (July 2026)
31 slides from Syntara's investor presentation, Jul 27, 2026
Slide 1: Investor Deck
For personal use only ™ Investor Deck Gary Phillips, CEO July 27th 2026
Slide 2: Forward Looking Statement
FORWARD LOOKING STATEMENT For personal use only This document contains risks, uncertainties and other forward-looking statements, factors, many of which are including statements beyond our control, and which concerning Syntara’s future may cause actual results to financial position, plans, and the d
Slide 3: Investment Highlights
INVESTMENT HIGHLIGHTS For personal use only Australian-founded Backed by Multiple shots on Funded into FY28 with clinical stage specialist healthcare goal from additional near term data to drive drug developer investors – Phase 2, Phase 1 and value over the next 44% institutional preclinical assets
Slide 4: Shareholders & Cash
SHAREHOLDERS & CASH Financial Information (ASX: SNT) Share Price & Volume - YTD Share price – 23 July 2026 $0.024 Close For personal use only Market cap A$47m 0.07 0.06 Cash balance (30 Jun 2026) A$13.5m 0.05 0.04 Enterprise value A$33.5m 0.03 0.02 0.01 Institutional Ownership 30 Jun 26 0 D&A Income
Slide 5: Three Assets Create Multiple Paths to Value
THREE ASSETS CREATE MULTIPLE PATHS TO VALUE A diversified clinical-stage pipeline across blood cancers, fibrosis and neurodegenerative disease ASSET INDICATION TOTAL ADDRESSABLE MARKET DEVELOPMENT STATUS For personal use only • Phase 2a clinical proof of concept in MF - complete Haematological Myelo
Slide 6: Amsulostat: Lead Asset and a Key Driver of Value
• FDA IND and orphan drug designation in For personal use only myelofibrosis • First and best in class pan-LOX inhibitor • Long patent life AMSULOSTAT: • Multiple Nature publications LEAD ASSET AND A KEY • Final Phase 2a trial data in combination with ruxolitinib presented at ASH 2025 DRIVER OF VALU
Slide 7: Lysyl Oxidases in Myelofibrosis
LYSYL OXIDASES IN MYELOFIBROSIS Amsulostat designed to improve the bone marrow microenvironment Amsulostat inhibits lysyl oxidase (LOX) activity and has a multi-faceted mode of action For personal use only Amsulostat ✓Inhibits cross-link formation ✓Reduces mechanical stress ✓Inhibits signalling of a
Slide 8: Myelofibrosis
MYELOFIBROSIS A rare type of bone marrow cancer that disrupts the body’s normal production of blood cells KEY FACTS Myelofibrosis characterised by a build up of scar tissue • Orphan disease affects ~55k people in 7MM (fibrosis) in bone marrow and abnormal proliferation of (USA, Japan, 5EU); USA ~ 20
Slide 9: Myelofibrosis: Limited treatment options currently
MYELOFIBROSIS Limited treatment options currently Current standard of care (SoC): JAK inhibitors Amsulostat For personal use only In contrast to SoC, amsulostat intervenes at the Key• Class Factsof drugs used in the management of splenomegaly source, inhibiting the family of lysyl oxidase (enlarged
Slide 10: MF-101 Add-on to JAK Inhibitor Ruxolitinib
MF-101 ADD-ON TO JAK INHIBITOR RUXOLITINIB Heterogenous population with a high disease burden STUDY DESIGN PATIENTS TREATED ENDPOINTS For personal use only Phase • 16 2a open label patients study recruited • Multi-national Phase 2a open to evaluate safety, PK/PD, PRIMARY label study to evaluate safe
Slide 11: Safety
SAFETY WHY THIS MATTERS Amsulostat well tolerated with Profile supportive of sustained use no treatment-related SAEs as add-on therapy of choice. For personal use only • Predominantly low-grade adverse events: • Supports combination use with JAK 74% of TEAS (63/85) were Grade 2 or lower. inhibitors
Slide 12: Total Symptom Score
TOTAL SYMPTOM SCORE Reduction at W24 Additional reduction past W24 73% (8/11) of patients achieved TSS50 at Week 24 or beyond * Pt continued past W38 # Pt completed W52 and study For personal use only Baseline TSS 37 10 52# 32 11* 18# 22# 45# 23# 10# 19# Symptom relief continues 0 for patients: TSS
Slide 13: Spleen Volume Reduction
SPLEEN VOLUME REDUCTION 44% (4/9) of patients achieved SVR25 at Week 24 or beyond For personal use only Improved spleen volume reduction: • At Week 24, 7/9 (78%) evaluable patients* experienced stable or reduced spleen volume with no increases in RUX dose • 4/9 (44%) evaluable patients achieved SVR2
Slide 14: Summary and Next Steps
SUMMARY AND NEXT STEPS Top-line Phase 2a data highlights amsulostat’s potential in MF Improvements of 50% or Meaningful spleen Of the 7 patients Differentiated TPP For personal use only more in total symptom volume reductions that completed 52 score (TSS50) (SVR) were observed weeks of treatment • C
Slide 15: Global Experts Supporting Amsulostat Development
SYNTARA APPOINTED GLOBAL EXPERTS SUPPORTING AMSULOSTAT DEVELOPMENT For personal use only Strategic Advisors to Myelofibrosis Clinical Syntara Board, Haematology Advisory Board • Dr Adam Craig • Professor Claire Harrison Former CEO of CTI BioPharma Corp, responsible Professor of Myeloproliferative Ne
Slide 16: BRIDGE-MF: Study Design
BRIDGE-MF: STUDY DESIGN Study designed to strengthen confidence in both efficacy and disease-modifying relevance Trial Design amsulostat Timeline of Activities For personal use only Main Cohort A 200 mg BID + • Patients with MF on ruxolitinib for min 3 months Preparation Phase ruxolitinib BID • Curr
Slide 17: Amsulostat: A New Future in MF Treatment Options
AMSULOSTAT: A NEW FUTURE IN MF TREATMENT OPTIONS Aspirational lifecycle development in MF enabled by first in class pan-LOX mechanism Ideal add-on for patients with Potentially best positioned Opportunity to slow For personal use only sub-optimal response to JAKi in frontline combination progression
Slide 18: Strong Interest in MF Assets from Strategics
STRONG INTEREST IN MF ASSETS FROM STRATEGICS Target / Acquiror / / / / / For personal use only DATE OF JULY-2026 APRIL-2026 MARCH-2026 DEC-2024 FEB-2024 ANNOUNCEMENT* Drug Name Navtemadlin AJ1-11095 Rovadicitinib Elritercept Pelabresib MDS and MF Myelofibrosis Lead Indication / Myelofibrosis Myelofi
Slide 19: Myelodysplastic Syndromes (MDS)
For personal use only Myelodysplastic Syndromes (MDS)
Slide 20: Indication Expansion: Myelodysplastic Syndrome (MDS)
INDICATION EXPANSION: Myelodysplastic Syndrome (MDS) Market Opportunity ~US$3.2b p.a. High unmet need Diverse bone marrow disorders characterized by inadequate production of healthy blood cells • Therapy for low-risk MDS patients is aimed at For personal use only improving cytopenia(s) to prevent co
Slide 21: Two Studies in MDS to Deliver Phase 1b Data
TWO STUDIES IN MDS TO DELIVER PHASE 1b DATA - 2H 2026 Generates additional interest from strategics AZALOX: MESSAGE: For personal use only Phase 1b/2a open label study to evaluate safety, PK/PD Phase 1b/2a open label study to evaluate safety, PK/PD and efficacy and efficacy • High risk MDS or interm
Slide 22: SNT-4728 for Neuroinflammation
SNT-4728: BRIEF HISTORY SNT-4728 FOR NEUROINFLAMMATION Safe and efficacious, small molecule enzyme inhibitor that crosses the For personal use only blood brain barrier A novel approach • Syntara discovered and wholly • Strong preclinical and clinical owned asset data support the role of SSAO • Drug
Slide 23: iRBD and Parkinson's
iRBD AND PARKINSON’S Using a sleep disorder to target Parkinson’s. KEY FACTS Early intervention to demonstrate neuroprotection – rather than late treatment when most neurons have already been lost (for example in PD) – is where disease-modifying, For personal use only • Patients with isolated REM sl
Slide 24: SNT-4728: Clinical Trial
SNT-4728: Study funded by Parkinson’s CLINICAL TRIAL UK Virtual Biotech and is being run at sites in Sydney, Australia and Oxford, UK Phase 2 multi-centre, placebo- For personal use only controlled study assessing effect of SNT-4728 on brain inflammation in patients with iRBD 40 patients (3:1 drug t
Slide 25: Baseline Exposure and Characteristics; Safety
BASELINE EXPOSURE AND CHARACTERISTICS SAFETY Study successfully recruited an In keeping with the excellent For personal use only enriched iRBD population at high safety profile observed in prior risk for phenoconversion to Phase 2 studies, SNT-4728 was safe Parkinson’s and related diseases and well
Slide 26: Reduction in Inflammation
REDUCTION IN Binding Potential (BPND) P-value INFLAMMATION Putamen Mean at Mean at Mean change (Paired t- test) baseline 12 weeks For personal use only Statistically significant Right 0.002918 -0.012073 -0.016 (0.033) 0.0145 reduction in brain inflammation observed unilaterally in the Left -0.001209
Slide 27: Skin Scarring
SKIN SCARRING Leverage expertise in LOX inhibition Standard of Care: Fragmented, Ineffective and Outdated • Silicone sheeting (none to very limited effect) • Skin Scarring is a Global Disease • Steroid injections (temporary; high relapse) For personal use only • Laser therapy (expensive; outcome ope
Slide 28: Clinical Proof of Concept Already Achieved
CLINICAL PROOF OF CONCEPT ALREADY ACHIEVED Placebo controlled study with first generation topical pan LOX inhibitor significantly de risks program SOLARIA2 Findings* For personal use only “We now understand the biology well enough to target stiffness directly rather than just calming inflammation ar
Slide 29: Innovative Trial Design to Evaluate Commercial Viability
INNOVATIVE TRIAL DESIGN TO EVALUATE COMMERCIAL VIABILITY Placebo controlled scar remodeling study with multiple efficacy readouts in H2 2026 For personal use only Healthy Volunteer Phase 1a Single Ascending Dose Trial design optimised for ✓ Dose-dependent target engagement confirmed inclusion criter
Slide 30: The Year Ahead - Poised to Deliver Near Term Value
THE YEAR AHEAD - POISED TO DELIVER NEAR TERM VALUE TARGET DRUG INDICATION PARTNERS PHASE 1 PHASE 2 ANTICIPATED NEWS FLOW HEALTHY H1 2026 H2 2026 PATIENTS PARTICIPANTS For personal use only FDA approved development plan Myelofibrosis Trial Progression and partner engagement Interim safety and High Ri
Slide 31: For personal use only
For personal use only Gary Phillips Chief Executive Officer gary.phillips@syntaratx.com.au Alison Findlay Head Business Development & Licensing alison.findlay@syntaratx.com.au http://syntaratx.com.au